Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2/STAT3 signaling pathway

Cellular senescence has emerged as a pivotal focus in cardiovascular research. This study investigates the previously unrecognized role of cellular senescence in septic cardiomyopathy (SCM) and evaluates senomorphic therapy using ruxolitinib (Rux) as a potential treatment option. We employed lipopol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of biological sciences 2024, Vol.20 (11), p.4314-4340
Hauptverfasser:	Yang, Boshen, Li, Taixi, Wang, Zhixiang, Zhu, Yuankang, Niu, Kaifan, Hu, Sien, Lin, Zhiqi, Zheng, Xinjie, Jin, Xian, Shen, Chengxing
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Cardiomyopathies - drug therapy Cardiomyopathies - metabolism Cellular Senescence - drug effects Disease Models, Animal Janus Kinase 2 - metabolism Lipopolysaccharides Male Mice Mice, Inbred C57BL Myocytes, Cardiac - drug effects Myocytes, Cardiac - metabolism Nitriles - pharmacology Nitriles - therapeutic use Pyrazoles - pharmacology Pyrazoles - therapeutic use Pyrimidines - pharmacology Pyrimidines - therapeutic use Rats Rats, Sprague-Dawley Sepsis - drug therapy Sepsis - metabolism Signal Transduction - drug effects STAT3 Transcription Factor - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!